TherapeuticsMD Inc
NASDAQ:TXMD
Intrinsic Value
TherapeuticsMD, Inc. operates as a pharmaceutical company. [ Read More ]
The intrinsic value of one TXMD stock under the Base Case scenario is 2.45 USD. Compared to the current market price of 1.86 USD, TherapeuticsMD Inc is Undervalued by 24%.
Valuation Backtest
TherapeuticsMD Inc
Run backtest to discover the historical profit from buying and selling TXMD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
TherapeuticsMD Inc
Current Assets | 11.8m |
Cash & Short-Term Investments | 4.3m |
Receivables | 3.1m |
Other Current Assets | 4.4m |
Non-Current Assets | 31.5m |
PP&E | 6.9m |
Intangibles | 6.1m |
Other Non-Current Assets | 18.5m |
Current Liabilities | 6.9m |
Accounts Payable | 27k |
Accrued Liabilities | 2.7m |
Other Current Liabilities | 4.1m |
Non-Current Liabilities | 7.2m |
Other Non-Current Liabilities | 7.2m |
Earnings Waterfall
TherapeuticsMD Inc
Revenue
|
1.3m
USD
|
Cost of Revenue
|
0
USD
|
Gross Profit
|
1.3m
USD
|
Operating Expenses
|
-9.8m
USD
|
Operating Income
|
-8.5m
USD
|
Other Expenses
|
-1.8m
USD
|
Net Income
|
-10.3m
USD
|
Free Cash Flow Analysis
TherapeuticsMD Inc
TXMD Profitability Score
Profitability Due Diligence
TherapeuticsMD Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
TherapeuticsMD Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
TXMD Solvency Score
Solvency Due Diligence
TherapeuticsMD Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
TherapeuticsMD Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TXMD Price Targets Summary
TherapeuticsMD Inc
According to Wall Street analysts, the average 1-year price target for TXMD is 5 USD .
Ownership
TXMD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TXMD Price
TherapeuticsMD Inc
Average Annual Return | -57.17% |
Standard Deviation of Annual Returns | 13.04% |
Max Drawdown | -99% |
Market Capitalization | 21.4m USD |
Shares Outstanding | 10 575 200 |
Percentage of Shares Shorted | 0.47% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 416 full-time employees. The company went IPO on 2001-01-31. Its contraceptive products include ANNOVERA. ANNOVERA (segesterone acetate (SA) and ethinyl estradiol (EE) vaginal system) is a one-year ring-shaped contraceptive vaginal system (CVS) and patient-controlled, procedure-free, reversible prescription contraceptive. Its menopause portfolio includes IMVEXXY and BIJUV. IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause. (estradiol and progesterone) capsules is a bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. Its prenatal vitamin products include vitaTrue, vitaPearl, and BocaGreenMD Prena1 True.
Contact
IPO
Employees
Officers
The intrinsic value of one TXMD stock under the Base Case scenario is 2.45 USD.
Compared to the current market price of 1.86 USD, TherapeuticsMD Inc is Undervalued by 24%.